QIAGEN Launches Targeted RNA Panels for Next-generation Sequencing

QIAGEN N.V. (NASDAQ:QGEN) reported the introduction of more than 170 new QIAseq Targeted RNA Panels for gene expression profiling, expanding QIAGEN’s portfolio of Sample to Insight solutions for next-generation sequencing (NGS).
According to the company’s press release:

The panels enable researchers to select from over 20,000 human genes and lncRNA to survey expression fold changes and discover interactions between genes, cellular phenotypes and disease processes.
The new QIAseq Targeted RNA Panels use innovative molecular barcode technology and built-in control assays to empower researchers with true digital RNA sequencing and accurate gene expression results. Coupled with world-leading RNA isolation technologies, integrated NGS library preparation and Ingenuity^® Pathway Analysis™ software, the panels provide a unique Sample to Insight solution for efficient RNA sequencing, using any NGS sequencer. Data analysis and insights are integrated into the QIAseq panels with easy-to-use, comprehensive analysis modules that require no bioinformatics expertise.

Brad Crutchfield, Senior Vice President and head of QIAGEN’s Life Sciences Business Area commented:

Our QIAseq panels make RNA sequencing more accurate and reproducible with molecular barcode-based sequencing addressing the challenges posed by low-abundance transcripts, PCR duplicates and amplification bias. These are important new tools for NGS researchers. QIAGEN is leading the way in providing NGS solutions to take labs from Sample to Insight.

Click here to view the full press release.